Avestar Capital LLC Acquires 447 Shares of AstraZeneca PLC (NASDAQ:AZN)

Avestar Capital LLC boosted its stake in shares of AstraZeneca PLC (NASDAQ:AZN) by 3.6% during the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 12,965 shares of the company’s stock after buying an additional 447 shares during the period. Avestar Capital LLC’s holdings in AstraZeneca were worth $1,010,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Martin Investment Management LLC boosted its stake in AstraZeneca by 2.8% in the 3rd quarter. Martin Investment Management LLC now owns 284,204 shares of the company’s stock worth $22,571,000 after purchasing an additional 7,615 shares during the period. Integrated Advisors Network LLC grew its holdings in shares of AstraZeneca by 46.6% during the third quarter. Integrated Advisors Network LLC now owns 43,610 shares of the company’s stock worth $3,398,000 after buying an additional 13,860 shares in the last quarter. Creative Planning raised its position in AstraZeneca by 8.0% in the 3rd quarter. Creative Planning now owns 224,751 shares of the company’s stock valued at $17,510,000 after buying an additional 16,692 shares during the last quarter. Northcape Wealth Management LLC acquired a new stake in AstraZeneca in the 2nd quarter valued at approximately $269,000. Finally, Cetera Advisors LLC boosted its position in AstraZeneca by 124.5% during the 1st quarter. Cetera Advisors LLC now owns 98,262 shares of the company’s stock worth $6,657,000 after acquiring an additional 54,488 shares during the last quarter. Institutional investors and hedge funds own 20.35% of the company’s stock.

Wall Street Analyst Weigh In

AZN has been the topic of a number of recent research reports. UBS Group upgraded shares of AstraZeneca from a “sell” rating to a “neutral” rating in a report on Wednesday, November 20th. TD Cowen increased their price objective on shares of AstraZeneca from $90.00 to $95.00 and gave the stock a “buy” rating in a research note on Monday, August 12th. Erste Group Bank upgraded AstraZeneca from a “hold” rating to a “buy” rating in a report on Wednesday, September 11th. Finally, Deutsche Bank Aktiengesellschaft upgraded shares of AstraZeneca from a “sell” rating to a “hold” rating in a research note on Wednesday, November 6th. Three analysts have rated the stock with a hold rating, seven have issued a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $89.75.

AstraZeneca Stock Performance

AZN opened at $66.36 on Wednesday. The company has a debt-to-equity ratio of 0.71, a current ratio of 0.93 and a quick ratio of 0.71. The company has a market capitalization of $205.76 billion, a PE ratio of 31.75, a price-to-earnings-growth ratio of 1.22 and a beta of 0.47. The business has a fifty day simple moving average of $72.94 and a 200 day simple moving average of $77.65. AstraZeneca PLC has a 1 year low of $60.47 and a 1 year high of $87.68.

AstraZeneca (NASDAQ:AZN) last announced its earnings results on Tuesday, November 12th. The company reported $1.04 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.01 by $0.03. AstraZeneca had a net margin of 12.68% and a return on equity of 30.01%. The company had revenue of $13.57 billion during the quarter, compared to analysts’ expectations of $13.08 billion. During the same quarter in the previous year, the business posted $0.87 earnings per share. AstraZeneca’s quarterly revenue was up 18.0% on a year-over-year basis. Research analysts expect that AstraZeneca PLC will post 4.1 EPS for the current year.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.